ABOUT US PRODUCT PIPELINE TECHNOLOGY PARTNERS  INVESTORS NEWS  CAREERS       Home  Contact  Search  Site Map   Corporate Profile  Financial Information  Corporate Governance  Reports & Presentations  Press Releases  IR Calendar & Events  Shareholder Services Sign up for messages to be conveniently delivered to your email whenever new company information is posted. Sign up here to receive Crucell's newsletter. Dutch    German                                 2006 |2005 | 2004 | 2003 | 2002 | 2001 | 2000   14 Nov 2001 Galapagos Genomics and Pharmacia enter Three Year Gene Target Identification Collaboration 22 Oct 2001 Galapagos Genomics and Procter & Gamble Pharmaceuticals Announce Functional Genomics Collaboration 22 Oct 2001 Crucell Announces 3rd Quarter 2001 Results 05 Oct 2001 Professor Ada Kruisbeek To Lead Crucell's Antibody Research 28 Sep 2001 Crucell Appoints Director of Business Development for its Biotherapeutics Production Platform 20 Sep 2001 Crucell Appoints Dr Jaap Goudsmit As Senior Vice President Vaccine Research 30 Aug 2001 Galapagos Genomics and VIB Announce Functional Genomics Collaboration in Alzheimer's Disease 29 Aug 2001 Crucell Appoints VP Corporate Development & Strategy 23 Aug 2001 Crucell announces the issuance of a major patent in the field of Phage Antibodies 22 Aug 2001 Galapagos Genomics and Vertex Pharmaceuticals in Gene Function Collaboration 16 Aug 2001 Crucell will be holding a Conference Call regarding the Centocor Agreement 16 Aug 2001 Crucell enters development and commercialization agreement with Centocor for human antibodies against cancer 24 Jul 2001 Crucell announces 2nd Quarter 2001 Results 11 Jul 2001 Crucell Presents Advact(TM), a New Improved Vaccine 28 Jun 2001 Crucell and Vaxin to jointly develop new type of vaccines which make injections obsolete 26 Jun 2001 Crucell signs PER.C6 license and production agreement with Selective Genetics 13 Jun 2001 Galapagos Genomics and Bayer Announce Functional Genomics Collaboration in Asthma Research 01 Jun 2001 Crucell presents Advac , a new improved vaccine technology 23 May 2001 Crucell boosts its target discovery and antibody development engine 15 May 2001 Crucell and University Medical Center Utrecht cooperate on Antibody and Vaccine treatment for Type 2 Diabetes 08 May 2001 Crucell announces First Quarter Results 26 Apr 2001 Crucell Q1 conference call invitation 10 Apr 2001 Crucell Appoints Executive Director of Business Development for its Antibody Business 03 Apr 2001 Crucell's PER.C6 Cell-Line Used In Merck's HIV-1 Vaccines Research Program 12 Mar 2001 Crucell's Revenues in 2000 Increase 116% 31 Jan 2001 Crucell Signs Production Agreement with DirectGene 15 Jan 2001 Crucell Signs Licensing Deal With Cell Genesys for PER.C6 Packaging Cell Technology 11 Jan 2001 Crucell Appoints Executive Director of Intellectual Property   Home    Contact    Search    Site Map
© Crucell 2006 | Disclaimer